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Background: Rotavirus (RoV) remains the leading cause of acute 
gastroenteritis in infants and children aged under five years in both 
high- and low-middle-income countries (LMICs). In LMICs, RoV 
infections are associated with substantial mortality. Two RoV vaccines 
(Rotarix and Rotateq) are widely available for use in infants, both of 
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which have been shown to be highly efficacious in Europe and North 
America. However, for unknown reasons, these RoV vaccines have 
markedly lower efficacy in LMICs. We hypothesize that poor RoV 
vaccine efficacy across in certain regions may be associated with 
genetic heritability or gene expression in the human host. 
Methods/design: We designed an open-label single-arm 
interventional trial with the Rotarix RoV vaccine to identify genetic and 
transcriptomic markers associated with generating a protective 
immune response against RoV. Overall, 1,000 infants will be recruited 
prior to Expanded Program on Immunization (EPI) vaccinations at two 
months of age and vaccinated with oral Rotarix vaccine at two and 
three months, after which the infants will be followed-up for diarrheal 
disease until 18 months of age. Blood sampling for genetics, 
transcriptomics, and immunological analysis will be conducted before 
each Rotarix vaccination, 2-3 days post-vaccination, and at each 
follow-up visit (i.e. 6, 12 and 18 months of age). Stool samples will be 
collected during each diarrheal episode to identify RoV infection. The 
primary outcome will be Rotarix vaccine failure events (i.e. 
symptomatic RoV infection despite vaccination), secondary outcomes 
will be antibody responses and genotypic characterization of the 
infection virus in Rotarix failure events. 
Discussion: This study will be the largest and best powered study of 
its kind to be conducted to date in infants, and will be critical for our 
understanding of RoV immunity, human genetics in the Vietnam 
population, and mechanisms determining RoV vaccine-mediated 
protection. 
Registration: ClinicalTrials.gov, ID: NCT03587389. Registered on 16 
July 2018.
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SAE: Serious adverse event
SUSAR: Suspected unexpected serious adverse reaction
OUCRU: Oxford university clinical research unit
CTU: Clinical trials unit
HLA: Human leukocyte antigen
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Background
Diarrhoea is the second leading cause of childhood morbidity 
and mortality globally1, with 27% of all diarrhoea-related 
deaths associated with rotavirus (RoV) infection2. RoV is the sin-
gle most important cause of acute gastroenteritis in infants and 
children under 5 years of age in high- and low-middle-income 
countries (LMICs)2. At the turn of the millennium, RoV 
was responsible for >125 million episodes of gastroenteri-
tis and over 400,000 deaths per year3,4. Although the median 
age of primary RoV infection is generally lower in develop-
ing countries (6–9 months) as compared to developed countries 
(2–5 years), nearly every child globally has been infected with 
RoV at least once by 5 years of age3. RoV belongs to the genus 
Reoviridae and is currently segregated into seven groups (A-G); 
Group A is the most dominant cause of gastroenteritis in 
humans5. Consequently, Group A RoVs are further character-
ized into genotypes according to variability in their glycopro-
tein (G) and protease-sensitive protein (P)5,6. Due to high genetic 
diversity, RoV can cause recurrent infections with different 
genotypes. Repeat infections are associated with decreasing 
severity, with several studies estimating that at least two 
RoV infections are sufficient to prevent further symptomatic 
infection7,8.
Two live-attenuated RoV vaccines have been licensed for use 
in infants since 20069,10. The availability of these vaccines 
and improved patient care has halved the global number of 
deaths attributable to RoV2,11. One of the currently licensed vac-
cines is Rotarix (GlaxoSmithKline, GSK), which is a monova-
lent formulation that comprises of the most dominant human 
genotype globally, G1[P8], and is recommended for use as a 
two-dose oral vaccine for infants between 6 and 24 weeks of 
age12. Rotarix was developed using a RoV strain isolated from 
a human and has been shown to be safe and immunogenic in 
humans. Notably, despite Rotarix being monovalent, the vac-
cine has been observed to provide at least partial protection 
against other circulating genotypes, including the less common 
G9[P8]13. The alternative vaccine is RotaTeq (Merck), which 
is a recombinant bovine-human pentavalent formulation con-
taining capsid proteins from the five most common disease-
causing variants in humans (i.e. G1, G2, G3, G4 and P8)12. 
RotaTeq is administered orally to infants in three doses at 2, 
4 and 6 months of age. Both Rotarix and RotaTeq have been 
shown to not impede immunological responses against other 
standard Expanded Programme on Immunization (EPI) vaccines 
(and vice versa), when administered together14–16. 
The initial safety, immunogenicity and efficacy studies for 
Rotarix and RotaTeq were conducted in Europe and North 
America17,18. Both Rotarix and RotaTeq were found to be 
highly immunogenic and efficacious in these settings, with 
significant protection observed against symptomatic RoV 
disease and severe forms of RoV gastroenteritis; vaccine effi-
cacy against RoV disease and severe gastroenteritis for Rota-
rix was >85% and >95%, and for RotaTeq >70% and 98%, 
respectively17–19. However, the high protective efficacy of 
these vaccines was not reproduced in LMIC, with studies in 
Bangladesh and Mali generating efficacies of 18% and 43%, 
respectively20–22. A potential explanation for regional differ-
ences in RoV vaccine protection is human genetic variation, 
which may impede the generation of an appropriate protective 
immune response. Vaccine studies conducted in twins have esti-
mated the genetic heritability of vaccine responses to be between 
39 and 89%23–26. It is only with recent advances in genomics 
and transcriptomics that we have been able to begin to identify 
these heritable traits27. Recent genome wide association studies 
(GWAS) following vaccination with hepatitis B and smallpox or 
after natural infection have identified several single-nucleotide 
polymorphisms (SNPs) associated with antibody responses28–35. 
Furthermore, early gene expression profiles have been 
described for several viral vaccines, including small pox, yellow 
fever, and influenza36–42. Functional genomics or transcriptomic 
studies were able to correlate early gene expression follow-
ing yellow fever or influenza vaccination with resulting T-cell 
and antibody responses43,44. Genomics and transcriptomics now 
permit the investigation of complex biological processes 
following vaccination and the identification of new corre-
lates that may predict protective vaccine responses. Despite 
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the importance of human genetics in vaccine-induced immune 
responses, GWAS and gene expression studies have yet to be 
conducted following RoV vaccination in infants. 
Rotavirus vaccination in urban Vietnam
Acute diarrhoeal disease remains a leading cause of morbidity 
and mortality in children aged under 5 years in Vietnam45–48. 
The community incidence of diarrhoeal illnesses in infants 
(<1 year of age) in southern Vietnam is estimated to be 271 per 
1,000 infant-years, of which >50% is RoV infection46. Both 
the Rotarix and RotaTeq have been tested and are licensed in 
Vietnam, but are not yet incorporated into the national immu-
nization program20,49. These vaccines induced incomplete 
protection when tested in Vietnamese populations, where immu-
nogenicity studies observed seroconversion to RoV-specific 
IgA in only 63.3% (95% CI: 54.3-71.6) of vaccinated 
Vietnamese infants49. Furthermore, a phase III, double blind, 
randomized control trial in Nha Trang, Vietnam observed a 
RoV vaccine efficacy of 63.9% (95% CI: 7.6 to 90.9) against 
severe RoV gastroenteritis20. The circulating strains (G1[P8] and 
G3[P8]) in that region of Vietnam at the time of the vaccine trials 
were similar to those circulating in high-income coun-
tries where vaccine efficacy was >97.5%50. Therefore, strain 
divergence is unlikely to explain the low vaccine efficacy in 
Vietnam. Differences in human genetics that underscore much 
of the variation in vaccine responses are also known to affect the 
immunogenicity and effectiveness of RoV vaccines51–53. These 
differences in heritable traits may underlie the reduced immuno-
genicity of RoV vaccines observed in Vietnamese infants and 
account for lower vaccine efficacy.
In summary, as the leading cause of morbidity and mortality 
from acute gastroenteritis in children under five years, RoV is 
a pathogen of global public health importance. At present, 
there are two World Health Organization (WHO)-approved 
RoV vaccines available. However, the efficacies of these two 
vaccines vary greatly between different geographical regions. 
Large gaps exist in our understanding of the immune processes fol-
lowing RoV vaccination, preventing the discovery of meaningful 
correlates of protection and effective vaccine development.
Objectives of the study
In this study we will stimulate the human immune system 
using the licensed Rotarix RoV vaccine and study how differ-
ences in host genotype and gene expression influence immune 
responses and vaccine failure. We hypothesize that human 
genetic and transcriptional variation may influence long-term 
protection from RoV diarrheal disease following RoV immuni-
zation in infants. Hence, the primary objective of the study is to 
investigate the impact of human genetic and transcriptional 
variation on immunological responses and long-term protec-
tion following RoV immunization in a population of infants 
in Ho Chi Minh City (HCMC), Vietnam. The secondary objec-
tives of the study are to assess temporal immunological 
responses following RoV vaccination, the function of maternally 
derived antibody in short-term immunity, and RoV genotypes 
associated with vaccine failure cases.
Methods
Study design
This study will be an open single arm, single centre, interven-
tional study conducted in HCMC, Vietnam. We aim to recruit 
1,000 infants aged between 8 and 9 weeks (2 months of age) to 
the study. These infants will receive two doses of Rotarix vac-
cine, with an interval of 28–37 days (or 4–5 weeks). The par-
ents will be requested to bring the infants to the study centre 
2–3 days following each Rotarix vaccination to receive the 
standard EPI vaccinations. The infants will then be under active 
surveillance for RoV-associated diarrhoea until the age of 
18 months. Blood samplings will occur pre- and post-vaccina-
tion (at 2 and 3 months of age) and at routine visits at 6, 12 and 
18 months of age (Table 1). A schematic diagram of the study 
is shown in Figure 1. Protocol version: Version 4.2, 3 January 
2018.
Inclusion criteria
Male and female infants aged between 8 and 9 weeks (approxi-
mately 2 months) attending Hung Vuong Hospital (HVH) 
to receive their standard EPI vaccinations will be invited to join 
the study. The infants must also be currently registered resi-
dents of the district or neighbouring districts of HCMC where 
the main study site is located (districts 1, 5, 6, 8, 10, or 11), 
with no specific intention of relocating in the next 18 months. 
Parents or guardians of all participating infants must provide 
written informed consent for their child to be enrolled in the 
study and agree to comply with study procedures, including 
human genetic studies. 
Exclusion criteria
Infants will be excluded from the study for any one of the 
below criteria:
▪  Refusal to consent by parent or guardian.
▪  Parent or guardian under 18 years of age.
▪  Premature birth (i.e. gestation period <37 weeks).
▪  Infants who have already been immunized with 
either a RoV vaccine or the standard 2-month EPI 
vaccinations.
▪  History of hypersensitivity to any components of the 
vaccine or adverse vaccine event.
▪  History of intussusception or congenital malformation 
of the gastrointestinal tract in the child that is likely to 
predispose child to intussusception.
▪  History of severe combined immunodeficiency disease 
(SCID), acquired immune deficiency syndrome (AIDS) 
or Human immunodeficiency virus (HIV) positivity, or 
other known immunodeficiency syndromes that may 
place the child at risk during immunisation.
Recruitment
Parents or guardians visiting HVH in HCMC, Vietnam with 
infants (between 8 and 9 weeks of age) for their check up and 
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Table 1. Sample types, time-points and purpose for collection throughout the study.
Sample No. Infant age Volume Purpose
Infant Blood
#1a 8 – 9 weeks (Rotarix 1st dose) 2 ml Serology, DNA, & RNA-seq
#2b 2–3 days post-1st Rotarix dose 1 ml RNA-seq
#3c
12 – 14 weeks (Rotarix 2nd dose, 28 – 37 
days after 1st dose of Rotarix)
2 ml RNA-seq, serology
#4d 2–3 days post-2nd Rotarix dose 1 ml RNA-seq
#5 26 weeks ± 4 weeks (Approx. 6 months) 1 ml Serology
#6 52 weeks ± 4 weeks (Approx. 12 months) 2 ml Serology
#7 78 weeks ± 4 weeks (Approx. 18 months) 2 ml Serology
Diarrhoeal stool Sample
Home visit N/A
Screen for RoV (and other 
enteric pathogens)
HTD visit N/A
Screen for RoV (and other 
enteric pathogens)
aBlood sample collected prior to the 1st dose of Rotarix.
bBlood sample collected prior to the 2-month standard EPI vaccination.
cBlood sample collected prior to the 2nd dose of Rotarix.
dBlood sample collected prior to the 3-month standard EPI vaccination.
Figure 1. A schematic diagram showing the study design, enrolment and sampling strategy for the study. Infants will be enrolled 
to the study between 8 to 9 weeks (i.e. approximately 2 months) of age and will receive the two doses of Rotarix at 2 months and 3 months of 
age. Then the 2nd and 3rd month standard EPI vaccinations will be given 2–3 days following each dose of Rotarix. Scheduled blood sampling 
will occur prior to each Rotarix dose and prior to the 2nd and 3rd month EPI vaccinations. Further scheduled blood sampling and surveillance 
(both passive and active) for diarrhoeal events will continue until the end of the study when infant reaches 18 months of age.
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EPI vaccinations will be referred to the study enrolment team 
if the infant fulfils all inclusion criteria. Recruitment activi-
ties will occur in the Pediatric Outpatient Clinic Department of 
Newborns of HVH only. A research nurse will explain the 
study, detail the risks and potential benefits, provide written 
information in the form of a brochure and invite the parents 
(or guardian) and infant to participate in the study. This study 
targets a vulnerable population, both in terms of the young 
infants and parents of the young infants. Therefore, following 
explanation of the study, sufficient time will be given for parents 
(or guardians) to make an informed decision whether to 
be involved. In all cases, written informed consent will be 
obtained prior to enrolment. The target sample size of 1,000 
participants will be enrolled within an anticipated duration of 
2 years. Following enrolment, a study nurse will ask the par-
ent or guardian details on baseline demographic, residential 
location, socioeconomics, health status of infant (and mother), 
specific risk factors for acquiring diarrhoeal diseases (such as 
water usage, sanitation and hygiene habits, concurrent familial 
illness) and vaccine history of the infant.
Intervention
The RoV vaccine that will be used in this study is the Rotarix 
vaccine manufactured by GSK Biologicals, which is licensed 
for use in Vietnam. All participating infants will receive 
two doses of Rotarix vaccine following standard Rotarix 
immunization protocol (as detailed by manufacturer). 
The participating infants will receive the 1st and 2nd dose of oral 
Rotarix at 2 months (i.e. between 8 and 9 weeks) and 3 months 
(i.e. between 12 and 14 weeks) of age, respectively, with 28–37 
days or 4–5 weeks between doses. If the infant regurgitates 
a majority of the vaccine dose, we will follow standard prac-
tice and give another dose of the vaccine. If the infant is hyper-
sensitive to the 1st dose of Rotarix, then the infant will not 
receive the 2nd dose and will be excluded from further par-
tipication the study. The participating infant will be observed 
for at least 30 minutes after vaccination for any significant acute 
reactions, with appropriate medical treatment readily avail-
able in case of anaphylactic reaction. Any adverse events occur-
ring during the observation period will be recorded. Parents 
and legal guardians will be instructed to contact the study team 
immediately should the infant manifest any signs or symptoms 
they perceive as serious or if the infant is admitted overnight to 
hospital. In the instance that the participating infant is expe-
riencing any form of acute diarrhoea (i.e. mild, moderate or 
severe), vomiting or any other acute illness, vaccination will 
be delayed until at least 72 hours after resolution of symp-
toms. A reminder call will be given four weeks after the 1st dose 
to remind parents to bring their infant back to HVH for the 
2nd dose of Rotarix to ensure the completion of the 2nd dose of 
Rotarix vaccine.
Blood sample collection and follow-up visits
Prior to receiving each dose of vaccine, the study nurses will 
collect a 2-ml blood sample from the participating infant; 
1 ml of blood will be immediately transferred into an appro-
priate ribonucleic acid (RNA)-preservation blood tube for 
transcriptomic analysis, and the remainder will be transferred 
into an ethylenediaminetetraacetic acid (EDTA)-containing blood 
tube for serology and genotyping. The parent or guardian will 
be requested to bring the infant for follow up visits 2–3 days 
after each dose of vaccine, and at 6, 12 and 18 months of age 
(Table 1). During these follow-up visits the study nurse will 
examine the infant, complete a questionnaire, collect a blood 
sample from the infant (1 ml at 2–3 days post-vaccination 
and at 6 months, and 2 ml at 12 and 18 months of age for tran-
scriptomics and/or serology) and then give the infant the appro-
priate EPI vaccinations. The blood for RNA sequencing will 
be frozen, while blood collected for deoxyribonucleic acid 
(DNA) sequencing and serology will be stored at ambient tem-
perature prior to being transported to the sample-processing 
laboratory within 24 hours of collection.
Passive and active surveillance for diarrheal events
A diarrhoeal event in this study will be defined as the occur-
rence of ≥3 non-formed stools (or ≥1, if bloody) in a 24 hour 
period26, and an increase in frequency, reduction in consist-
ency or notable change in quality of the stools, compared to 
what the parent or guardian considers to be normal for the 
child27. As part of the research activity, diarrhoeal events will 
be passively and actively surveyed to measure diarrhoea cas-
ued by RoV infection (despite RoV vaccination). Passive and 
active surveillance for diarrhoea will begin one week after 
the 1st Rotarix dose, and continue up until the study partici-
pant completes or reaches the end of the study. Procedure for 
passive and active diarrhoea surveillance will be conducted 
similar to a recently completed cohort study (Figure 2)54. 
In order to perform passive surveillance for diarrhoeal events 
in study infants, parents will be requested to alert a mem-
ber of study staff when the child experiences an episode of 
diarrhoea through calling or texting a study nurse or doctor. 
Additionally, for active surveillance, a designated family mem-
ber will be contacted weekly by phone (short message service 
[SMS] or call) inquiring if the enrolled child has experienced 
an episode of diarrhoea in the preceding seven days. If diar-
rhoea is confirmed by the family member, a study nurse will 
be made aware and they will call the family to arrange a mutu-
ally convenient time for a household visit. At the household, 
a short disease history research questionnaire will be adminis-
tered, which will include details of illness onset, illness of close 
contacts, dehydration status and other clinical symptoms. The 
study nurse will clinically evaluate the child and advise as to 
whether hospital attendance is needed. Oral rehydration 
and electrolytes supplements will be provided to the fam-
ily. Study nurses will be trained carefully to ensure that patients 
seek treatment when necessary. The nurse will provide clini-
cal advice and will recommend whether the parent seeks 
standard of care at a local healthcare facility. At the house-
hold visit, the study nurse will collect a stool sample from the 
child if a specimen is available at the time of visit. If no sam-
ple is available at the visit, the study nurse will give the family 
a sterile container and will arrange for collection and transport 
within 24 hours.
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If an infant experiences an episode of diarrhoeal disease that 
the parent feels is severe enough to seek medical care, we 
will request the parents to alert one of our study nurses and to 
consider attending Hospital for Tropical Diseases (HTD) in 
District 5, HCMC for consultation. If the family attends 
HTD for diarrhoeal illness, they will be requested to call a 
study nurse or doctor prior to their visit to alert study staff that 
they are coming. Following clinical examination of the infant, 
the study nurses will collect a stool sample and complete 
a study questionnaire. The infant will then be treated with 
standard care for diarrheal disease.
Adverse event (AE) and serious adverse events (SAEs)
On the days of Rotarix administration and 2–3 days later, 
the study nurse will report any observed adverse events. The 
participant’s parents or guardians will also be asked to report 
any observed adverse events during their post-vaccination vis-
its (2–3 days post-vaccination) and follow-up visits (at 6, 12 
and 18 months of infant age). Furthermore, the participant’s 
parents or guardians will be urged to immediately report any SAE 
or suspected unexpected serious adverse reactions (SUSARs) 
to the study team immediately. For SAEs, investigators will 
notify the Oxford University Clinical Research Unit (OUCRU) 
Clinical Trials Unit (CTU) within 24 h. SAEs and SUSARs will 
be notified to the OUCRU CTU until trial closure. CTU will 
perform an initial check of the report and request any additional 
information if required and ensure review by an independent 
medical monitor. Furthermore, CTU will report all SAEs to 
the Ministry of Health (as is the regulation for clinical trials) 
and to GSK, Vietnam. Since Rotarix is a licensed vaccine and 
Figure 2. Flowchart showing the strategy for active and passive surveillance of diarrheal events in the participating infants 
following RoV vaccination up until end of study at 18 months of age.
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proven to be safe for use in infants, the parents will not be asked 
to keep a diary card to closely monitor and record all adverse 
reactions.
On-site monitoring
A site initiation visit will be conducted for each study site by 
staff from the OUCRU CTU. All essential site staff including 
the PI, lead pharmacist and lead research nurse must be in 
attendance. The initiation training will include training in 
the vaccine administration and practices, as well as the trial 
procedures. Monitoring will then be carried out approximately 
annually at each site by OUCRU CTU staff. The monitors 
will require access to all participant medical records definded 
as source document. The investigator (or delegated deputy) 
should work with the monitor to ensure that any problems 
detected are resolved.
Geospatial mapping
Residential household addresses of the participanting infants 
will be obtained from parents and guardians. Then geo-
graphical co-ordinates of their residence will be asertained 
using the residential household addresses for the purpose of 
descriptive and correlational spatial epidemiology. The coor-
dinates will be entered into a geographical information sys-
tem (GIS), such as ArcView (ESRI Inc., Redlands, CA, USA). 
To protect patient confidentiality all maps arising from this 
research will display data at low resolutions in efforts to 
prevent identification of individual households.
Laboratory methods
Blood Samples: Whole blood from the EDTA tubes will be sep-
arated into blood cells (red cells and buffy coats) and plasma. 
Human DNA will be extracted from blood cells and stored 
at -20°C until required for genotyping. The plasma will be 
aliquoted into cryo-vial tubes for storage at -20°C until required 
for serology. RoV-specific antibodies in plasma will be assessed 
using conventional RoV enzyme-linked immunosorbent assay 
(ELISA)55–57. Blood will be collected into blood RNA tubes 
(which lyses cells and preserves RNA) and then stored at 
-80°C until RNA extraction for transcriptomic studies.
Stool samples: All stool samples will be screened for enteric 
parasites, bacteria and viruses using established laboratory 
methods, for example multiplex real-time polymerase chain 
reaction (PCR) and/or the xTAG gastrointestinal pathogen 
panel (Luminex Molecular Diagnostics, Austin, TX, USA). 
The xTAG multiplex assay will screen stool samples for 
enteric pathogens, including RoV A, Salmonella species (spp.), 
Shigella spp., Campylobacter spp., C. difficile (toxins A and 
B), enterotoxigenic E. coli (ETEC) heat labile and heat sta-
ble enterotoxins, E. coli O157, Shiga toxin-producing E. coli 
spp., Vibrio cholerae, Yersinia enterocolitica, fecal adenovirus 
40/41, norovirus GI/GII, Giardia spp., E. histolytica, and Crypt-
osporidium spp58. The remaining stool sample rest will be stored 
at -80°C until further use. In samples that test positive for RoV, 
we will conduct whole genome sequencing of RoV using a 
recently developed a sensitive sequencing method that can 
successfully sequence RoV genomes from clinical faecal 
samples with over >90% genome coverage59. Briefly, this tech-
nique involves antibody capture of whole rotaviral particles 
from faecal samples and subsequent amplification with whole 
RoV genome sequencing (Illumina MiSeq).
Human genetic studies
For genetic studies, extracted anonymised-linked DNA will 
undergo genotyping using a DNA microarray or sequencing60. 
For transcriptomics studies, RNA will be extracted from the 
anonymised blood RNA tubes using standard methods61. 
Standard quality control procedure will be undertaken to 
assess the suitability of the isolated RNA for sequencing, 
including (but not limited to), the assessment of RNA integ-
rity and concentration. RNA that passes these quality control 
checks will then undergo library creation for sequencing. This 
library creation will include protocols to deplete globin RNAs 
and select polyadenylated messenger RNAs, to maximise 
sequencing coverage of RNAs from white blood cell types. The 
RNA libraries will then be sequenced and analyzed.
End of study
Participation in the study will end once the study participants 
have completed the follow-up visit at 18 months of age. Lost-
to-follow-up cases are defined as those participants that the 
study team are unable to reach after a minimum of three docu-
mented attempts over a period of two months after a missed 
visit. The study participants may withdraw consent and all fur-
ther study contacts at any time when their parents or guard-
ians decide. The study participants will be withdrawn by the 
chief investigators if found not to meet inclusion or exclusion 
criteria or the study requirements after starting the study.
Outcome measures
The primary outcome will be Rotarix vaccine failure events (i.e. 
symptomatic RoV infection) from the first dose of vaccination 
to 18 months.
The secondary outcomes will include:
Quantification of the antibody response following immuni-
zation. The temporal kinetics and properties of RoV-specific 
antibody responses following immunization will be used to 
investigate the effect of human genetics, maternally trans-
ferred antibodies, and geospatial and epidemiological factors 
that may impact on humoral response following vaccination. 
An assessment of infecting RoV genotypes in vaccine failure 
cases will be performed to investigate whether vaccine failure 
cases are a result of varying RoV genotypes.
Sample size justification
A recent study conducted passive surveillance for diarrhoeal 
cases and estimated the incidence of diarrhoeal cases in Vietnam 
in infants during their first year of life as 271 cases per 
1,000 infant years46. However, an active surveillance study 
for diarrhoea in Vietnam identified twice as many diarrhoeal 
cases as in passive surveillance62. Therefore, the true incidence 
of diarrhoea in Vietnam is approximately 540 cases per 1,000 
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infant years. The aetiological agent of 53% of the identified 
diarrhoeal cases was RoV46, which estimates the average 
incidence of RoV in Vietnam to 286 cases per 1,000 infant 
years. Since the proposed study follows each participant for 
18 months, we would expect to observe 429 cases per 1,000 
infants (i.e. 286 cases x 1.5 years) during the study period. Phase 
III RoV clinical trials in a Vietnamese cohort observed 64% 
vaccine efficacy within the first two years after vaccination20. 
Using a vaccine efficacy of 64%, the incidence of RoV vaccine 
failure cases can be approximated to 155 diarrhoeal cases 
per 1,000 infants.
Although not established as a correlate of protection, high 
titres of RoV-specific antibodies are associated with protec-
tion in vaccine efficacy studies (risk ratio=0.5)63. Investigating 
associations between humoral immunity and RoV vaccine fail-
ure events is an important aspect of this study. Using a risk 
ratio of 0.5 for high RoV-specific antibody tires (i.e. >90 U/ml), 
we can calculate the probability of a vaccine failure event 
in high antibody titre group as being 7.8% (while 15.5% for 
antibody titres lower than 90 U/ml). Using a power of 80% 
we estimate a minimum of 144 vaccine-failure events are 
required to observe a difference at 95% confidence level. A 
conservative recruitment of a sample size of 1,000 infants will 
lead to 155 vaccine-failure events, which is above the minimum 
vaccine-failure events required to power the study at 80%. 
Analysis
Epidemiological, antibody and geospatial analyses. The primary 
endpoint, i.e. the proportion of vaccine success in protection 
against diarrheal disease caused by RoV, will be estimated 
by the number of individuals who do not experience a 
diarrheal episode caused by RoV after vaccination and until 
18 months of age. Descriptive analyses will be performed to 
explore the variation in geospatial, demographic, socioeconomic 
factors and antibody titres between infants with RoV associated 
diarrhoea (aka vaccine failure events) and infants protected from 
RoV associated diarrhoea. Statistical analysis will be con-
ducted using parametric and non-parametric tests; Chi-square 
or Fisher’s exact test will be used for categorical variables and 
Student’s t-test or Kruskal-Wallis tests for continuous data, 
respectively.
Genetic association and transcriptomic analyses. Integrating 
genome-wide genotype data with serial measurements of 
the transcriptional and humoral responses to RoV vaccine in 
a longitudinal study should allow us to identify genes that 
influence vaccine responsiveness and subsequent immunity 
to RoV. Genotypes will be called using genotype calling 
software packages for microarrays (e.g. optiCall)64, or variant calling 
pipelines for whole-genome sequencing data (e.g. GATK)65. 
To assess variants that are not on the genotyping array, impu-
tation and phasing will be conducted using imputation 
software (e.g. PBWT) using a publicly available reference panel 
(e.g. 1,000 Genomes, or Haplotype Reference Consortium 
panel). The reference panel will be augmented in the Human 
leukocyte antigen (HLA) region by HLA sequencing of a subset 
of the study cohort (e.g. Histogenetics). We will also use the SNP 
data to accurately impute ABO blood groups and secretor status. 
Standard sample and marker quality control procedures will be 
applied. Quantitative trait loci (QTL) models will be built to 
detect associations between genetic variation and variation in 
gene expression. Linear regression-based association models will 
also be built using response variables including antibody titres 
and cases of vaccine failure.
The quality of sequencing reads will be evaluated (e.g. using 
FastQC) and poor-quality reads/adapter contamination will be 
filtered out or trimmed (e.g. cutadapt, Trimmomatic). Reads from 
ribosomal RNA or non-human contamination will also be 
filtered out (e.g. SortMeRNA). Reads will be aligned to the 
human reference assembly (e.g. TopHat, STAR) and align-
ment quality will be evaluated (e.g. QualiMap). Transcript abun-
dances will be quantified (e.g. Salmon, kallisto) and batch effects 
detected and removed (e.g. EDASeq, PEER, sva). Transcript 
abundances will also be assessed for other biases such as length 
or GC bias. Transcripts (or sets of transcripts) that are differ-
entially expressed (or differentially spliced) between experi-
mental groups (e.g. time points or high vs. low responders) will 
be identified (e.g. DESeq, edgeR, limma/voom), with appropri-
ate covariates (e.g. gender) included in the model. To increase 
statistical power and biological interpretability, transcripts will 
be grouped into sets such as co-expression networks or transcrip-
tomic modules. Existing modules generated in previous systems 
vaccinology studies will also be leveraged, and new modules 
will be generated and annotated (e.g. using gene set enrichment 
analyses based on Gene Ontology/pathway databases). From 
these differentially expressed/spliced transcripts (or modules), 
we will aim to identify signatures that correlate with and/or 
predict important endpoints such as antibody titre or vaccine 
failure. We will also investigate the utility of computational 
deconvolution methods for obtaining immune cell subtype- 
specific gene expression profiles from bulk expression data, in 
order to conduct analyses in a cell-type specific manner.
Best practices in the field of statistical genetics (both genetic 
and transcriptomic) are constantly evolving, hence computa-
tional analyses will be adapted to include improved tools and 
pipelines as they become available. We will also develop statisti-
cal methods for modelling multi-omic studies with longitudinal 
sampling.
Data management and storage
Participant data collected at HVH site and during home vists 
will be recorded using laptops and tablets directly on to elec-
tronic case report forms (eCRFs) on a secure password- 
protected electronic database. Electronic data entry devices 
will be password protected and accessible only by authorised 
users. Any information collected on the laptops or tablets will 
be sent immediately to the secure OUCRU server and no infor-
mation will be retained on the devices. Paper CRFs will be 
used during diarrhoeal illness presentations at the HTD study 
clinic and study nurses will transfer data from paper CRFs 
onto the password-protected electronic database. Paper CRFs 
will be provided to the CTU at OUCRU, who store them in 
long-term storage in the restricted storage facility at the HTD. 
Laboratory data from anonymised-linked (i.e. identified by an 
enrolee identifier only) pathogen screening will be recorded on 
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the standard study laborartory forms and subsequently input into 
a secure password-protected electronic database by a member 
of the study team.
The access control restrictions for this data are as follows: 
All systems (including computers, storage systems, portable 
devices, and the users and administrators who control that 
equipment) which are used to store, process, or transmit unen-
crypted data must limit access to authorised individuals only, 
who are members of an access control group designated by the 
WSI Principal Investigator (Anderson) and to WSI systems 
administrators. Data stored on (or transmitted via) systems that 
do not implement the required access control restrictions will 
be suitably encrypted.
The present clinical trial will not involve a data monitoring 
committee (DMC) since the interventional product, Rotarix, 
being given to infants is licensed and the safety profile is well 
characterized. 
Participant confidentiality
Parents/guardians will be assured that all information gener-
ated in this study will remain confidential. The names and 
addresses of study participants will be recorded in the database 
but kept separate from the main body of data and access will 
be strictly controlled through password protection. Any sci-
entific publications or reports will not identify any child by 
name or initials. When the research team reviews their notes, 
they are also bound by professional confidentiality. All genetic 
data resulting from this study will be de-identified using 
current best practices. Anonymized DNA and RNA sequence 
data will be archived indefinitely in the European Genome- 
phenome Archive (EGA) and shared with other researchers 
around the world via a managed access system.
Data sharing
In line with research transparency and greater data access, 
this trial is registred at ClinicalTrials.gov and a data sharing 
policy is in place. This policy is based on a controlled access 
approach with a restriction on data release that would compro-
mise an ongoing trial or study. Data exchange will comply with 
Information Governance and Data Security Policies in all of 
the relevant countries. In order to protect participant privacy 
and confidentiality, only anonymised data will be shared with 
collaborators. Anonymised DNA and RNA sequence data will 
be archived indefinitely in the European Genome-phenome 
Archive (EGA), a research database managed by the European 
Molecular Biology Laboratory (EMBL) European Bioinfor-
matics Institute (EBI), Hinxton, Cambridge, UK. Anonymised 
genetic data relating to human research participants will be 
stored according to the WSI Human Data Security Policy. Data 
for this project will fall into the WSI Data Security Level 2 
category.
Publications
No aspect of this study will be reported without approval from 
all principle investigators. In line with Wellcome Trust policy 
that the results of publicly-funded research should be freely 
available, manuscripts arising from the trial will, wherever 
possible, be submitted to peer-reviewed journals which enable 
Open Access via UK PubMed Central (PMC) within six months 
of the official date of final publication. All publications will 
acknowledge the trial’s funding sources.
Ethics approval and consent to participate
The current study has received ethical approval from the 
Oxford Tropical Research Ethics Committee (OxTREC, study 
reference 56-16), the internal review board (IRB) of Hung 
Vuong Hospital (HVH), the IRB of Hospital for Tropical Dis-
eases (HTD) and from the ethics committee in biomedical stud-
ies at the Ministry of Health in Vietnam. Any future protocol 
amendments prior to implementation will require review by 
ethical committees of HVH, HTD and OxTREC. The present 
trial is also registered at ClinicalTrials.gov (NCT03587389). 
Parents or guardians of all infant participants will provide written 
informed consent prior to participation of infant in the study.
Discussion
Diarrheal disease caused by RoV is still the leading cause 
of morbidity due to gastroenteritis in children under 2 years 
of age globally2,46. Two RoV vaccines are licensed for use in 
humans and have shown high efficacy against RoV-caused gas-
troenteritis in western countries, but poor efficacy has been 
observed in parts of Africa and Asia, including Vietnam13,16,17,20. 
It is unclear why RoV vaccine has such variable efficacy in 
different parts of the world. Since vaccination is currently one 
of the only methods of infection control, it is imperative that 
we understand the cause of RoV vaccine failure and work 
towards improving its efficacy. This study aims to investi-
gate host factors as a possible explanation for differences in 
immune responses and efficacy of RoV vaccines.
Numerous studies have identified the role of human genet-
ics and gene expression in dictating immunological responses 
(including humoral and cellular responses) to natural infection 
and vaccine response23,28,31,41,44,66. Technological advances now 
allow us to screen entire genomes and transcriptomes of indi-
viduals faster and at an economical cost67. Therefore, the 
current study takes a systems biology approach to investi-
gate the host genetic and transcriptomic factors influencing 
both immunological responses and RoV vaccine failure (ver-
sus success) in the Vietnamese population. This study will be 
the first systems biology investigation for RoV vaccines and 
also the first such study conducted within the Vietnamese popu-
lation. A major strength of the study is the large sample size 
will allow us to power the study to investigate the contribution 
of host genetic and transcriptomic factors to an epidemio-
logically relevant clinical end point, i.e. gastroenteritis due to 
RoV vaccine failure events. The genetic and transcriptional 
factors required for humoral responses to RoV will also be 
deciphered in the current study. Furthermore, active and pas-
sive surveillance for diarrhoea following vaccination will allow 
us to sequence the viral genomes of breakthrough RoV infec-
tions. However, due to the absence of a no vaccination con-
trol group, we will be unable to assess the true diversity of RoV 
circulating during the study. If the current study is successful in 
identifying both genomic and transcriptomic factors that are asso-
ciated with protective vaccines responses, then we can foresee 
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these findings being utilized to design more immunogenic 
vaccines or more personalized vaccines to different populations 
of individuals.
Trial status




No underlying data are associated with this article.
Extended data
Zenodo: The influence of human genetic variation on early 
transcriptional responses and protective immunity following 
immunization with Rotarix vaccine in infants in Ho Chi Minh 
City in Vietnam: A study protocol for an open single-arm 
interventional trial. https://doi.org/10.5281/zenodo.407533268.
Appendix A contains the World Health Organization Trial 
Registration Data Set.
Reporting guidelines
Zenodo: Appendix B contains the PRISMA-P checklist for ‘The 
influence of human genetic variation on early transcriptional 
responses and protective immunity following immunization 
with Rotarix vaccine in infants in Ho Chi Minh City in 
Vietnam: A study protocol for an open single-arm interventional 
trial’. https://doi.org/10.5281/zenodo.407533268.
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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Julie Bines   
Department of Paediatrics, The University of Melbourne, Melbourne, Australia 
This protocol has been registered on clinicaltrials.gov in July 2018 and started recruitment in 
March 2019. Therefore the comments on this study design and approach to the research 
questions defined I appreciate will likely have limited impact on the conduct of the study. While 
the intention of the study is novel, the ability to achieve the stated outcomes based on the 
information presented presents some concern. These are summarised below:
Clarification about the primary and secondary endpoints. There is confusion with key 
endpoints on page 5 and page 9. If the primary endpoint is “vaccine failure” events then this 
seems primarily a vaccine effectiveness study. 
 
1. 
Antibody responses to be used to determine the secondary outcomes are not 
defined. Presumably this is anti-rotavirus serum IgA, but there is confusion on page 5 on 
implying that maternally derived antibodies are to be compared. As there is a primary 
interest in immune responses and genetics there seems a missed opportunity to look more 
broadly at immune responses including innate and adaptive immune responses. If serology 
is for sIgA seroresponses – this needs to be defined (i.e. is this seroconversion post 
vaccination when compared to a baseline prevaccination blood or an increase above a 
threshold?). For most studies assessing immune response for Rotarix the primary outcome 
is on the 28 day post dose 2 blood using a >3 fold rise from baseline (for seroconversion) or 
>20 for a sero-response – noting that in this setting some infants may have a sero-response 
at baseline. Since there is no blood draw at this timepoint it is difficult to know how the 
results of this study will compare with previous studies in this and similar 
environments. Where is analysis to be performed?  
 
2. 
This paper seems to have some out of date information and needs to be revised with 
respect to new data, for example:
Page 4 all children have a rotavirus infection by 5 years is from a publication prior to 
rotavirus vaccines – now in >100 country NIP. Appreciate that this may be still true in 
Vietnam. 
1. 
There are 4 rotavirus vaccines now WHO prequalified not 2 (page 2 and 4) with 2. 
3. 
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updated data on the effectiveness of these vaccines across may settings.
It is not correct to say that it is unclear why vaccines have less efficacy in LIMCs – 
there is a consensus that a number of factors may contribute to a greater or less 
extent in different settings.
3. 
Update the data on rotavirus vaccine uptake in the private market including the 
locally licensed and manufactured Rotavin vaccine. 
 
4. 
There is no biological hypothesis provided to why genetic and transcriptional information 
may impact responses, and whether there is sufficient variation within the study population 
to identify if there are differences. Is it likely that any differences identified might have a 
broad role of immune responses and not just to rotavirus vaccines? It would seem 
reasonable to measure immune responses to the other EPI to determine this. 
 
4. 
There is no reference to the considerable data on histoblood group antigen status which 
does have a solid basis for genetic influence rotavirus vaccine responses based its the role 
as a receptor for rotavirus in the gut.  
 
5. 
There are concerns about the calculation of the sample size. The investigators quote vaccine 
efficacy data from the Phase III Rotarix study of 65% as a basis for 
their estimation. However this is based on reduction in severe rotavirus gastroenteritis 
episodes (Vesikari score >11). The impact of vaccines on mild or moderate rotavirus 
gastroenteritis is lower in both LIMCs and high income countries. This study does not seem 
to make a distinction between severity of episodes in their analysis or calculation of SS. The 
characteristics of the immune responses will likely be very different in severe and mild 
episodes so this will provide a challenge in interpretation of data. 
 
6. 
No information is provided on the EPI vaccines which will also impact immune responses 
and/or vaccine take of Rotarix (as is the case for OPV).
7. 
 
Is the rationale for, and objectives of, the study clearly described?
Partly
Is the study design appropriate for the research question?
Partly
Are sufficient details of the methods provided to allow replication by others?
Partly
Are the datasets clearly presented in a useable and accessible format?
Not applicable
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expertise to confirm that it is of an acceptable scientific standard, however I have 
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significant reservations, as outlined above.
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